Clinical Trial Update: A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules [Phase 2]

View source ↗

Summary

This Phase 2 trial update describes safety and immunogenicity results for the MenABCWY meningococcal vaccine given on two dosing schedules.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• MenABCWY

Snippet

Sponsor: Pfizer | Conditions: Meningococcal Vaccine | Phase 2 | Status: COMPLETED | Results posted: 2025-01-08